Dr. Mark Mulligan, director of the NYU Langone Vaccine Center, received his medical degree from the University of Texas Southwestern Medical School in Dallas, and trained in internal medicine and infectious diseases at the University of Alabama at Birmingham. He has conducted virology and immunology research, and vaccine clinical and translational research, for 31 years. In October 2018 he became the director of the Division of Infectious Diseases and Immunology, the Jeffrey P. Bergstein Professor of Medicine, and a professor of microbiology at the NYU School of Medicine and NYU Langone Medical Center in New York City. His research focus includes vaccine clinical trials and translational studies of human immune responses to pathogens and/or vaccines. From 2007 to 2018, he was the principal investigator for the National Institute of Allergy and Infectious Diseases (NIAID)‐funded Emory Vaccine and Treatment Evaluation Unit (VTEU), one of nine national units funded by the National Institutes of Health (NIH). In addition, he served as a multiple principal investigator (MPI) for the NIAID‐funded Emory‐CDC HIV/AIDS Clinical Trials Unit (CTU), conducting HIV/AIDS and TB research in Atlanta, Kenya, the Philippines, and Thailand. His research laboratory performs endpoint microbiology and immunology assays for these human studies. Dr. Mulligan served from 2009 to 2018 as the program director for the Emory Vaccinology Training Program NIH T32, whose purpose is to train a new generation of vaccinology research leaders.